This is the authors' abstract. We don't add key points for this paper.
Objective: This study describes the design, synthesis, and biological evaluation of novel imidazole-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine-1,2,3-triazole hybrids acting as potent inhibitors of the epidermal growth factor receptor (EGFR) in lung cancer pathways. Methods: A series of 1,2,3-triazole derivatives (VIIa–VIIo) was synthesized via a one-pot 1,3-dipolar cycloaddition reaction of 6-(chloromethyl)-3-(1-methyl-1H-imidazol-2-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine 8,8-dioxide (V) with sodium azide and various aryl alkynes at 60°C. The in vitro antiproliferative activity of these newly developed hybrids was evaluated against human lung cancer cell lines using the standard MTT cell viability assay. Results and Discussion: The chemical structures of all synthesized compounds were unambiguously confirmed by ESI-MS, 1H, and 13C NMR spectroscopy. Hybrids VIIl and VIIm demonstrated pronounced cytotoxic profiles, exhibiting IC50 values ranging from 2.09 ± 0.25 to 5.09 ± 0.58 μM against the targeted cancer cells, which is comparable to the clinical reference drug erlotinib. Notably, in vitro kinase assays revealed that compound VIIm possesses exceptional EGFR inhibitory efficacy (IC50 = 0.36 ± 0.02 μM), fully surpassing the potency of erlotinib (IC50 = 0.42 ± 0.02 μM). Conclusions: A novel library of imidazole-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine-1,2,3-triazole conjugates was successfully validated as effective anticancer leads. The most active compounds exhibited significant selectivity, showing negligible toxicity toward the non-malignant HEK293 cell line. In silico molecular docking simulations confirmed that the highly active derivatives possess superior binding affinities, with energy scores spanning from –9.98 to –10.88 kcal/mol, compared to erlotinib (–7.69 kcal/mol). Consequently, minor structural optimizations of scaffolds VIIl and VIIm offer a highly promising strategic direction for developing next-generation therapeutic candidates in targeted lung cancer oncology.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Raju et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: